Evidence map›Paper›PMID 36034693›Full record

ArticleFrontiers in cellular and infection microbiology2022

Dmitry Kopelyanskiy, Chantal Desponds, Florence Prevel, Matteo Rossi, Romain Migliorini, Tiia Snäkä, Remzi Onur Eren, Stéphanie Claudinot, Lon-Fye Lye, Manolis Pasparakis and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 3 countries.

Dmitry KopelyanskiyDepartment of Biochemistry, University of Lausanne, Epalinges, Switzerland.
Chantal DespondsDepartment of Biochemistry, University of Lausanne, Epalinges, Switzerland.
Florence PrevelDepartment of Biochemistry, University of Lausanne, Epalinges, Switzerland.
Matteo RossiDepartment of Biochemistry, University of Lausanne, Epalinges, Switzerland.
Romain MiglioriniDepartment of Biochemistry, University of Lausanne, Epalinges, Switzerland.
Tiia SnäkäDepartment of Biochemistry, University of Lausanne, Epalinges, Switzerland.
Remzi Onur ErenDepartment of Biochemistry, University of Lausanne, Epalinges, Switzerland.
Stéphanie ClaudinotDepartment of Biochemistry, University of Lausanne, Epalinges, Switzerland.
Lon-Fye LyeDepartment of Molecular Microbiology, School of Medicine, Washington University, St. Louis, MO, United States.
Manolis PasparakisInstitute for Genetics, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD) and Center for Molecular Medicine, University of Cologne, Cologne, Germany.
Stephen M BeverleyDepartment of Molecular Microbiology, School of Medicine, Washington University, St. Louis, MO, United States.
Nicolas FaselDepartment of Biochemistry, University of Lausanne, Epalinges, Switzerland.
University of Lausanne · CHWashington University in St. Louis · USCologne Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases · DEUniversity of Cologne · DE

Funding

GLYCOSYLATION MUTANTS OF LEISHMANIAR01AI031078 · NIAID · WASHINGTON UNIVERSITY · PI BEVERLEY, STEPHEN M · 1992 to 2019
$11.4M
MOLECULAR GENETICS OF LEISHMANIA USING DNA TRANSFECTIONR01AI029646 · NIAID · WASHINGTON UNIVERSITY · PI BEVERLEY, STEPHEN M · 1990 to 2015
$9.3M
Leishmania RNA viruses and pathogenesisR01AI130222 · NIAID · WASHINGTON UNIVERSITY · PI BEVERLEY, STEPHEN M · 2018 to 2022
$3.3M
NIAID NIH HHS R01 AI029646NIAID NIH HHS R01 AI031078NIAID NIH HHS R01 AI130222
6 · The paper itself

Abstract

Inducible nitric oxide synthase (iNOS) is essential to the production of nitric oxide (NO), an efficient effector molecule against intracellular human pathogens such as

Indexed as

LeishmaniaLeishmania guyanensisNitric Oxide Synthase Type IIAnimalsCytokinesHumansInterleukin-17LeishmaniavirusMiceNF-kappa BNitric OxideToll-Like Receptor 3CytokinesInterleukin-17NF-kappa BNitric OxideNitric Oxide Synthase Type IIToll-Like Receptor 3IL-17Ainducible nitric oxide synthase (iNOS)LeishmaniaLeishmania RNA virus 1 (LRV1)metastasisnuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB)tumor necrosis factor-alpha-induced protein 3 (A20)type I Interferons

Identifiers

PMID36034693
PMCPMC9416488
OpenAlexW4290861339

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.